Galanthaminone
Based on 1 Customer Validation
Galanthaminone (Narwedin) is a competitive and reversible cholinesterase (AChE) inhibitor; is used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.85%
- CAS 番号: 510-77-0
- 分子式: C17H19NO3
- 分子量:285.34
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
生物活性
|
AChE |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BJ | IC50 |
>50 μM
Compound: 17
|
Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay
Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
| CCRF-CEM | IC50 |
31.6 μM
Compound: 17
|
Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay
Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
| G-361 | IC50 |
>50 μM
Compound: 17
|
Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay
Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
| HeLa | IC50 |
>50 μM
Compound: 17
|
Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay
Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
| K562 | IC50 |
>50 μM
Compound: 17
|
Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay
Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
| MCF7 | IC50 |
>50 μM
Compound: 17
|
Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay
Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay
|
[PMID: 22921081] |
Galanthaminone reduces the action of AChE and therefore tends to increase the concentration of acetylcholine in the brain. is also an allosteric ligand at nicotinic acetylcholine receptors. It has shown activity in modulating the nicotinic cholinergic receptors on cholinergic neurons to increase acetylcholine release.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 510-77-0
-
性状 Solid
-
分子量 285.34
-
分子式 C17H19NO3
-
Color White to off-white
-
SMILES
O=C1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(O[C@@]3([H])C1)=C24
-
別名
(-)-Narwedine; Narwedin
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 10 mg/mL (35.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (3.50 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (3.50 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Greenblatt HM, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [Content Brief]
[2]. Heinrich M, et al. Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004 Jun;92(2-3):147-62. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5046 mL | 17.5228 mL | 35.0455 mL | 87.6139 mL |
| 5 mM | 0.7009 mL | 3.5046 mL | 7.0091 mL | 17.5228 mL | |
| 10 mM | 0.3505 mL | 1.7523 mL | 3.5046 mL | 8.7614 mL | |
| 15 mM | 0.2336 mL | 1.1682 mL | 2.3364 mL | 5.8409 mL | |
| 20 mM | 0.1752 mL | 0.8761 mL | 1.7523 mL | 4.3807 mL | |
| 25 mM | 0.1402 mL | 0.7009 mL | 1.4018 mL | 3.5046 mL | |
| 30 mM | 0.1168 mL | 0.5841 mL | 1.1682 mL | 2.9205 mL |